Celldex Therapeutics share price today

(CLDX)

Celldex Therapeutics share price is $24.77 & ₹2,107.80 as on 24 Dec 2024, 2.30 'hrs' IST

$24.77

▲

-0.37

(-1.47%)

Market is closed - opens 8 PM, 24 Dec 2024

View live Celldex Therapeutics share price in Dollar and Rupees. Guide to invest in Celldex Therapeutics from India. Also see the sentimental analysis on Indian investors investing in Celldex Therapeutics. Get details on the Indian mutual funds that are investing in Celldex Therapeutics. Get Analyst recommendations and forecasts along with all the Celldex Therapeutics's financials.

Celldex Therapeutics share price movements

Today's Low: $24.15
Today's High: $25.39
$24.77
2.5%
Downside
Day's Volatility :4.88%
Upside
2.44%
52 Weeks Low: $22.93
52 Weeks High: $53.18
$24.77
7.43%
Downside
52 Weeks Volatility :56.88%
Upside
53.42%

Celldex Therapeutics Returns

Period	Celldex Therapeutics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-38.62%	-10.6%	0.0%
6 Months	-30.57%	-6.0%	0.0%
1 Year	-37.49%	2.2%	0.0%
3 Years	-39.9%	-0.9%	-21.1%

Celldex Therapeutics Key Statistics

in dollars & INR

Previous Close	$25.14
Open	$24.9
Today's High	$25.39
Today's Low	$24.15
Market Capitalization	$1.7B
Today's Volume	$2.1M
52 Week High	$53.18
52 Week Low	$22.9291
Revenue TTM	$10.0M
EBITDA	$-171.1M
Earnings Per Share (EPS)	$-2.58
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-29.84%

How to invest in Celldex Therapeutics from India?

It is very easy for Indian residents to invest directly in Celldex Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Celldex Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Celldex Therapeutics or CLDX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Celldex Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Celldex Therapeutics shares which would translate to 0.034 fractional shares of Celldex Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Celldex Therapeutics, in just a few clicks!

Returns in Celldex Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

Celldex Therapeutics investment value today

Current value as on today

₹63,925

Returns

₹36,075

(-36.07%)

Returns from Celldex Therapeutics Stock

₹38,414 (-38.41%)

Dollar Returns

₹2,339 (+2.34%)

Indian investors sentiment towards Celldex Therapeutics

-41%

Period: Sep 24, 2024 to Dec 23, 2024. Change in 30 Days versus previous period

Search volume for Celldex Therapeutics on INDmoney from India has reduced in the last 30 days as on Dec 24, 2024. -41% less investors are searching Celldex Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Celldex Therapeutics

Wellington Management Company LLP
13.93%
FMR Inc
9.08%
BlackRock Inc
7.07%
Vanguard Group Inc
5.83%
Kynam Capital Management, LP
5.21%
Eventide Asset Management, LLC
5.02%

Analyst Recommendation on Celldex Therapeutics

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Celldex Therapeutics(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Celldex Therapeutics

What analysts predicted

Upside of 170.89%

Current:

$24.77

Target:

$67.10

Insights on Celldex Therapeutics

Price Movement
In the last 3 months, CLDX stock has moved down by -37.4%
Increasing Revenue
Revenue is up for the last 3 quarters, 156.0K → 3.19M (in $), with an average increase of 57.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -32.80M → -42.12M (in $), with an average decrease of 13.4% per quarter
CLDX vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 28.5% return, outperforming this stock by 64.8%
CLDX vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 26.3% return, outperforming this stock by 66.4%
Price to Sales
ForCLDX every $1 of sales, investors are willing to pay $153.3, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.9 for every $1 of sales.

Celldex Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$9.5M	↓ 25.15%
Net Income	$-151.2M	↑ 62.51%
Net Profit Margin	-1.6K%	↓ 855.01%

	FY19	Y/Y Change
Revenue	$3.6M	↓ 62.54%
Net Income	$-50.4M	↓ 66.68%
Net Profit Margin	-1.4K%	↑ 175.27%

	FY20	Y/Y Change
Revenue	$7.4M	↑ 107.61%
Net Income	$-59.8M	↑ 18.68%
Net Profit Margin	-805.88%	↑ 603.92%

	FY21	Y/Y Change
Revenue	$4.7M	↓ 37.3%
Net Income	$-70.5M	↑ 17.95%
Net Profit Margin	-1.5K%	↓ 710.16%

	FY22	Y/Y Change
Revenue	$2.4M	↓ 49.32%
Net Income	$-122.8M	↑ 74.13%
Net Profit Margin	-5.2K%	↓ 3693.25%

	FY23	Y/Y Change
Revenue	$6.9M	↑ 192.02%
Net Income	$-141.4M	↑ 15.19%
Net Profit Margin	-2.1K%	↑ 3154.53%

	Q2 FY23	Q/Q Change
Revenue	$268.0K	↓ 72.29%
Net Income	$-30.5M	↑ 36.08%
Net Profit Margin	-11.4K%	↓ 9063.35%

	Q3 FY23	Q/Q Change
Revenue	$1.5M	↑ 466.04%
Net Income	$-38.3M	↑ 25.43%
Net Profit Margin	-2.5K%	↑ 8859.26%

	Q4 FY23	Q/Q Change
Revenue	$4.1M	↑ 172.31%
Net Income	$-43.3M	↑ 13.19%
Net Profit Margin	-1.0K%	↑ 1473.76%

	Q1 FY24	Q/Q Change
Revenue	$156.0K	↓ 96.22%
Net Income	$-32.8M	↓ 24.24%
Net Profit Margin	-21.0K%	↓ 19982.45%

	Q2 FY24	Q/Q Change
Revenue	$2.5M	↑ 1501.28%
Net Income	$-35.8M	↑ 9.25%
Net Profit Margin	-1.4K%	↑ 19595.94%

	Q3 FY24	Q/Q Change
Revenue	$3.2M	↑ 27.74%
Net Income	$-42.1M	↑ 17.52%
Net Profit Margin	-1.3K%	↑ 114.84%

	FY18	Y/Y Change
Profit	$9.5M	↓ 25.15%

	FY19	Y/Y Change
Profit	$-39.1M	↓ 509.93%

	FY20	Y/Y Change
Profit	$-35.1M	↓ 10.19%

	FY21	Y/Y Change
Profit	$1.6M	↓ 104.51%

	FY22	Y/Y Change
Profit	$957.0K	↓ 39.55%

	FY23	Y/Y Change
Profit	$3.9M	↑ 304.91%

	Q2 FY23	Q/Q Change
Profit	$-488.0K	↓ 302.49%

	Q3 FY23	Q/Q Change
Profit	$750.0K	↓ 253.69%

	Q4 FY23	Q/Q Change
Profit	$3.4M	↑ 349.6%

	Q1 FY24	Q/Q Change
Profit	$-619.0K	↓ 118.36%

	Q2 FY24	Q/Q Change
Profit	$1.7M	↓ 374.8%

	Q3 FY24	Q/Q Change
Profit	$3.2M	↑ 87.6%

	FY18	Y/Y Change
Operating Cash Flow	$-75.2M	↓ 24.71%
Investing Cash Flow	$29.8M	↓ 35.84%
Financing Cash Flow	$29.4M	↓ 42.6%

	FY19	Y/Y Change
Operating Cash Flow	$-46.4M	↓ 38.31%
Investing Cash Flow	$17.1M	↓ 42.72%
Financing Cash Flow	$16.3M	↓ 44.78%

	FY20	Y/Y Change
Operating Cash Flow	$-40.4M	↓ 12.95%
Investing Cash Flow	$-98.2M	↓ 675.05%
Financing Cash Flow	$171.2M	↑ 953.24%

	FY21	Y/Y Change
Operating Cash Flow	$-60.9M	↑ 50.75%
Investing Cash Flow	$-216.2M	↑ 120.08%
Financing Cash Flow	$272.4M	↑ 59.07%

	FY22	Y/Y Change
Operating Cash Flow	$-103.7M	↑ 70.31%
Investing Cash Flow	$89.9M	↓ 141.61%
Financing Cash Flow	$4.1M	↓ 98.5%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-27.2M	↓ 4.81%
Investing Cash Flow	$1.2M	↓ 97.79%
Financing Cash Flow	$133.0K	↓ 80.84%

Celldex Therapeutics Technicals Summary

Sell

Neutral

Buy

Celldex Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Celldex Therapeutics Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Celldex Therapeutics, Inc.	-10.66%	-30.57%	-37.49%	-39.9%	1017.33%
Regeneron Pharmaceuticals, Inc.	-6.36%	-34.48%	-17.38%	10.57%	87.23%
Biontech Se	-6.36%	34.01%	7.97%	-55.63%	240.6%
Alnylam Pharmaceuticals, Inc.	-2.21%	2.2%	28.37%	52.34%	108.41%
Vertex Pharmaceuticals Incorporated	-13.96%	-16.16%	-2.55%	78.68%	80.37%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Celldex Therapeutics, Inc.	NA	NA	0.0	-2.4	-0.3	-0.2	NA	11.85
Regeneron Pharmaceuticals, Inc.	17.51	17.51	1.06	45.07	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.11	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.17	0.55	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Celldex Therapeutics, Inc.	Buy	$1.7B	1017.33%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$77.8B	87.23%	17.51	33.61%
Biontech Se	Buy	$26.7B	240.6%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$30.8B	108.41%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$102.1B	80.37%	32.84	-4.51%

Celldex Therapeutics Dividend announcements

Celldex Therapeutics Earnings
Celldex Therapeutics’s price-to-earnings ratio stands at None
Read More

About Celldex Therapeutics

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im

Organization	Celldex Therapeutics
Employees	160
CEO	Mr. Anthony S. Marucci M.B.A.
Industry	Health Technology

Management People of Celldex Therapeutics

Name	Title
Mr. Anthony S. Marucci M.B.A.	Founder, President, CEO & Director
Dr. Tibor Keler Ph.D.	Founder, Chief Scientific Officer & Executive VP
Mr. Sam Martin CPA	Senior VP, CFO, Secretary & Treasurer
Dr. Margo Heath-Chiozzi M.D.	Senior Vice President of Regulatory Affairs
Dr. Diane C. Young M.D.	Senior VP & Chief Medical Officer
Prof. Joseph P. Schlessinger Ph.D.	Co-Founder & Member of Scientific Advisory Board
Ms. Sarah Cavanaugh	Senior Vice President of Corporate Affairs & Administration
Mr. Freddy A. Jimenez Esq.	Senior VP & General Counsel
Dr. Ronald A. Pepin	Chief Business Officer & Senior VP
Ms. Elizabeth Crowley	Chief Product Development Officer & Senior VP

Important FAQs about investing in Celldex Therapeutics from India :

What is Celldex Therapeutics share price today?

Celldex Therapeutics share price today stands at $24.77, Open: $24.90 ; Previous Close: $25.14 ; High: $25.39 ; Low: $24.15 ; 52 Week High: $53.18 ; 52 Week Low: $22.93. The stock opens at $24.90, after a previous close of $25.14. The stock reached a daily high of $25.39 and a low of $24.15, with a 52-week high of $53.18 and a 52-week low of $22.93.

Can Indians buy Celldex Therapeutics shares?

Yes, Indians can invest in the Celldex Therapeutics (CLDX) from India.

With INDmoney, you can buy Celldex Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Celldex Therapeutics at zero transaction cost.

How can I buy Celldex Therapeutics shares from India?

It is very easy to buy Celldex Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Celldex Therapeutics be purchased?

Yes, you can buy fractional shares of Celldex Therapeutics with INDmoney app.

What are the documents required to start investing in Celldex Therapeutics stocks?

To start investing in Celldex Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.